Company intelligence / Profile preview

Guangzhou Evidence-Based Medicine Technology

Guangzhou, Guangdong, China

Ownership: Private
Employees: ~796
Development stage: Other

Overview

LBP SYSTEM’s diagnostic reagents and instruments are commercially available in China, with multiple products certified by the CE mark and recognized by Japanese and British health authorities. Their technologies serve over 2,400 medical institutions in pathology screening, digital imaging, and companion diagnostics for cancer[2][4][7].

Therapeutic areas: OncologyWomen's HealthRare Diseases
Modalities: Liquid-Based CytologyImmunohistochemistryFluorescence In Situ HybridizationDigital Pathology & Artificial Intelligence
Industry: Molecular Diagnostics

Partnerships

Pharmaceutical companies for companion diagnostics

Beyond the preview

Go deeper on Guangzhou Evidence-Based Medicine Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Guangzhou Evidence-Based Medicine Technology.

Explore the full profile